Home » Stocks » VRTX

Vertex Pharmaceuticals, Inc. (VRTX)

Stock Price: $217.04 USD 0.60 (0.28%)
Updated Feb 24, 2021 4:00 PM EST - Market closed
After-hours: $216.51 -0.53 (-0.24%) Feb 24, 7:51 PM
Market Cap 56.42B
Revenue (ttm) 6.21B
Net Income (ttm) 2.71B
Shares Out 259.84M
EPS (ttm) 10.29
PE Ratio 21.09
Forward PE 18.12
Dividend n/a
Dividend Yield n/a
Trading Day February 24
Last Price $217.04
Previous Close $216.44
Change ($) 0.60
Change (%) 0.28%
Day's Open 215.82
Day's Range 214.72 - 220.42
Day's Volume 1,775,785
52-Week Range 197.47 - 306.08

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 2 weeks ago

The Vanguard Health Care Fund (Trades, Portfolio) has released its portfolio for the fourth quarter. Major trades include selling out of Medtronic PLC (NYSE:MDT), Merck & Co Inc. (NYSE:MRK) an...

Other stocks mentioned: BMY, MDT, MRK, PFE, UNH
Forbes - 2 weeks ago

The stock price of Vertex Pharmaceuticals has seen a decline of 7% over the last five trading days, while it's down 11% over the last ten trading days. This drop can largely be attributed to t...

The Motley Fool - 2 weeks ago

Here's why you should still pick up shares of this high-flying biotech.

The Motley Fool - 3 weeks ago

Don't get caught chasing the hype.

Other stocks mentioned: AAPL, GH
Seeking Alpha - 3 weeks ago

Vertex Q4 2020 revenue grew 15% y/y. The pipeline of potential drugs is strong.

The Motley Fool - 3 weeks ago

Investors were not pleased with the company's latest quarterly update.

GuruFocus - 3 weeks ago

Analysts applauded Vertex Pharmaceuticals' (NASDAQ:VRTX) fourth-quarter and full-year 2020 results, but voiced skepticism about the company's ability to maintain its momentum.

Zacks Investment Research - 3 weeks ago

Vertex (VRTX) reports missing earnings estimates in the fourth quarter of 2020, while revenues surpass the same. The company provides revenues guidance for 2021.

Market Watch - 3 weeks ago

Shares of Vertex Pharmaceuticals Inc. were down 4.3% in trading on Tuesday, the day after the company discussed its deal-making strategy with analysts during its fourth-quarter earnings call. ...

The Motley Fool - 3 weeks ago

The biotech simply didn't perform well enough to please Wall Street, but better news could be on the way.

Seeking Alpha - 3 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q4 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 weeks ago

Vertex (VRTX) delivered earnings and revenue surprises of -5.28% and 2.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 3 weeks ago

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) fell 1.1% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 47.65% year over year to $2.51...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2020 and provi...

Zacks Investment Research - 3 weeks ago

Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.

Other stocks mentioned: AMZN, BABA, CMG, CRUS, F, GOOGL, ON, PFE, QCOM, TMUS, UPS
The Motley Fool - 3 weeks ago

These companies offer opportunistic investors the perfect blend of growth and value.

Other stocks mentioned: AGNC, CRM
The Motley Fool - 3 weeks ago

You can still find deeply discounted stocks if you do a little digging.

Other stocks mentioned: ALXN, CVS, T, VZ, WBA
Zacks Investment Research - 3 weeks ago

Vertex (VRTX) gets FDA clearance for the investigational new drug application of VX-880, for the potential treatment of type I diabetes.

Benzinga - 3 weeks ago

Vertex Pharmaceuticals (NASDAQ:VRTX) unveils its next round of earnings this Monday, February 01. Get prepared with Benzinga's ultimate preview for Vertex Pharmaceuticals's Q4 earnings.

Zacks Investment Research - 3 weeks ago

Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 3 weeks ago

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Crocs (CROX), AGCO Corporation (AGCO), Meritage Homes (MTH) and Vertex Pharma...

Other stocks mentioned: AGCO, CROX, MTH
The Motley Fool - 3 weeks ago

These leaders in their respective niches all have tremendous growth prospects.

Other stocks mentioned: ISRG, TDOC
Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND, enabling the company to procee...

Zacks Investment Research - 3 weeks ago

Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.

Other stocks mentioned: GILD, LLY, MRK, SNY
Zacks Investment Research - 3 weeks ago

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta.

Zacks Investment Research - 4 weeks ago

Vertex's (VRTX) sNDA seeking approval for Trikafta to treat cystic fibrosis in children has been accepted by the FDA.

Business Wire - 4 weeks ago

BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Applic...

Zacks Investment Research - 4 weeks ago

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $241.31, moving +1.57% from the previous trading session.

Zacks Investment Research - 4 weeks ago

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 4 weeks ago

It's a big bet but not a big gamble.

Other stocks mentioned: EDIT, GH, ISRG, TDOC, XBI
Seeking Alpha - 1 month ago

After plummeting by more than 20% in October from news of drug trial discontinuation, VRTX's price performance has largely been lackluster. However, its Cystic Fibrosis lineup remains robust a...

The Motley Fool - 1 month ago

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Other stocks mentioned: CRSP, EDIT, JNJ, SPY, VTI
Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close....

The Motley Fool - 1 month ago

Buying fast-growing, innovative businesses is a pathway to financial success.

Other stocks mentioned: GRWG, LOVE, SE
Zacks Investment Research - 1 month ago

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Motley Fool - 1 month ago

These hypergrowth stocks might be the perfect place to park your stimulus money.

Other stocks mentioned: OKTA, PINS
The Motley Fool - 1 month ago

This company has what it takes to generate earnings growth in the near term and the long term.

The Motley Fool - 1 month ago

These companies offer some of the most innovative technologies in the life sciences industry.

Other stocks mentioned: CRSP
Zacks Investment Research - 1 month ago

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $225.55, marking a -0.25% move from the previous day.

The Motley Fool - 1 month ago

If you sell too quickly, you'll miss out on billions of dollars in product revenue -- and share performance.

Other stocks mentioned: ABT
The Motley Fool - 1 month ago

Sometimes, bigger really is better.

Other stocks mentioned: AZN, CRM, KL, PANW
Seeking Alpha - 1 month ago

Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

The Motley Fool - 1 month ago

One big biotech and two small biotechs that share a common denominator: Great growth prospects.

Other stocks mentioned: EXEL, NVAX
Zacks Investment Research - 1 month ago

Vertex Pharmaceuticals (VRTX) closed at $237 in the latest trading session, marking a +1.76% move from the prior day.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at...

The Motley Fool - 1 month ago

These stocks can handle whatever the new year has in store.

Other stocks mentioned: DXCM, REGN
The Motley Fool - 1 month ago

The highflying Nasdaq 100 is hiding some serious value in plain sight.

Other stocks mentioned: DXCM, FB
Zacks Investment Research - 1 month ago

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, EDIT, MRNS, NTLA
The Motley Fool - 1 month ago

The young bull market is beginning to stretch its legs, and these high-growth companies should be direct beneficiaries.

Other stocks mentioned: CRM, MA, NEE
InvestorPlace - 1 month ago

These top stocks to buy in January have impending upside triggers and can be interesting to investors through 2021. The post 4 Top Stocks to Buy in January appeared first on InvestorPlace.

Other stocks mentioned: CLA, WMT, XPEV

About VRTX

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitr... [Read more...]

Industry
Biotechnology
IPO Date
Jul 24, 1991
Stock Exchange
NASDAQ
Ticker Symbol
VRTX
Full Company Profile

Financial Performance

In 2020, VRTX's revenue was $6.21 billion, an increase of 49.07% compared to the previous year's $4.16 billion. Earnings were $2.71 billion, an increase of 130.42%.

Financial Statements

Analyst Forecasts

According to 28 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is 284.73, which is an increase of 31.19% from the latest price.

Price Target
$284.73
(31.19% upside)
Analyst Consensus: Buy